Synapse - Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results Meeting Abstract

Authors:	Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; Modi, S.; Seidman, A.; Drullinsky, P.; Partridge, A.; Schapira, L.; Wulf, G.; Gilewski, T.; Atieh, D.; Mayer, E.; Isakoff, S.; Sugarman, S.; Fornier, M.; Traina, T.; Bromberg, J.; Currie, V.; Robson, M.; Burstein, H.; Overmoyer, B.; Ryan, P.; Kuter, I.; Younger, J.; Schumer, S.; Tung, N.; Zarwan, C.; Schnipper, L.; Chen, C.; Winer, E.; Norton, L.; Hudis, C.
Abstract Title:	Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
Meeting Title:	31st Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	69
Issue:	2 Suppl.
Meeting Dates:	2008 Dec 10-14
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2009-01-01
Start Page:	189S
Language:	English
ACCESSION:	ISI:000262583200396
PROVIDER:	wos
DOI:	10.1158/0008-5472.SABCS-2108
Notes:	--- - Meeting Abstract: 2108 - Suppl. S - "Source: Wos"